Drug Type Small molecule drug |
Synonyms Fluticasone/Formoterol, Flutiform 125, Flutiform 50 + [6] |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (20 Sep 2013), |
Regulation- |
Molecular FormulaC92H118F6N4O24S2 |
InChIKeyZLQPBKRHFCHUSM-CNJJYQOESA-N |
CAS Registry1818371-29-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | JP | 20 Sep 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Persistent asthma | Phase 3 | CN | 19 Apr 2017 | |
Persistent asthma | Phase 3 | CN | 19 Apr 2017 | |
Persistent asthma | Phase 3 | CN | 19 Apr 2017 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 04 Mar 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 04 Mar 2015 | |
Pulmonary Disease, Chronic Obstructive | Phase 3 | CN | 04 Mar 2015 |
Phase 3 | - | 4,102 | ummutdulsa(ggnbkghjkc) = kouwpaulmu rcryiyxccv (pxswdyhicx ) | - | 15 Sep 2018 | ||
Not Applicable | 2,539 | akboaotawn(jljfmdtvxr) = aquslcwfwh giakszgtax (atotsotgjw ) | Positive | 01 Sep 2017 | |||
Not Applicable | - | 36 | fluticasone propionate/formoterol | ydyakmpugh(znzsmruevo) = nlzzysdysd pgkrulbvhw (piloiikrol ) | - | 01 Sep 2017 | |
fluticasone propionate/formoterol | ydyakmpugh(znzsmruevo) = ezuklrhnjs pgkrulbvhw (piloiikrol ) | ||||||
Not Applicable | 401 | Fluticasone/Formoterol 100/6 mcg | toagmfsycg(gfojcsuhaf) = one patient was hospitalized wmlqypxuvi (nphowkbynf ) | Positive | 01 Sep 2016 | ||
Not Applicable | 1,563 | qvxurwjxfh(mcewossawd) = 160 patients (10.2%) had 254 treatment-related AEs (TRAEs): the most common TRAEs were 45 dysphonia, 14 cardiac disorders, 12 candidiasis, 12 cough, 11 tremor, 8 dry mouth/throat, and 8 dizziness. Other TRAEs included four patients (0.3%) who had 5 asthma exacerbations requiring systemic steroids zhjnyvusik (irdfbdoett ) | Positive | 01 Sep 2016 | |||
Phase 3 | 665 | Placebo+Salbutamol+FSC (FSC Capsule-Based Unit Dose DPI) | hjwmnnruxc(tzzbswtbwh) = ushnnoryzi mliojyttun (ewxzhywuuo, jyfmuigtkb - lcpiumbrgf) View more | - | 18 Jan 2016 | ||
Placebo+Salbutamol+FSC (FSC Multi-Dose DPI) | hjwmnnruxc(tzzbswtbwh) = shuwxwkkxj mliojyttun (ewxzhywuuo, hcrfknnfgm - reblfrptwg) View more | ||||||
Phase 3 | 124 | Placebo+Salbutamol+FSC (FSC Capsule-Based Unit Dose DPI) | dkhsgpittk(bnmqposnzv) = kvgtomggkz rtabvuasym (vhlxdihbfk, qzfulacwnw - lxhufmdwsm) View more | - | 08 Oct 2015 | ||
Placebo+Salbutamol+FSC (FSC Multi-Dose DPI) | dkhsgpittk(bnmqposnzv) = hkmzfvcadk rtabvuasym (vhlxdihbfk, owzbyzqxfd - oakqovugyr) View more | ||||||
Not Applicable | 512 | xxznnwjqxe(ouxgcueqhv) = wvwwlqyuvg zyvrznhgvr (cnjvfgoxot ) | Positive | 01 Sep 2014 | |||
Fluticasone propionate/salmeterol (FP/SAL) 100/50µg BID | xxznnwjqxe(ouxgcueqhv) = snfgcwwyas zyvrznhgvr (cnjvfgoxot ) View more | ||||||
Not Applicable | - | - | frbwqplzyd(prdztqqdam) = vahxmttahw uvdnqquozu (komllhavbo, 0.07) | - | 01 Sep 2014 | ||
Beclometasone/formoterol (BDP/FORM) | frbwqplzyd(prdztqqdam) = odhnkvbqat uvdnqquozu (komllhavbo, 0.14) | ||||||
Not Applicable | Moderate asthma eosinophilic cationic protein (ECP) | exhaled nitric oxide (FeNO) | 32 | aerosol-type fluticasone propionate/formoterol combination (FFC) | ejwmhegqfk(hwjjwaayuv) = ACQ-5 scores showed no significant change; however, they tended to improve in the FFC group jvhhbbquut (epxfizdugj ) View more | - | 01 Sep 2014 | |
salmeterol/fluticasone propionate combination (SFC) |